Keratinocyte growth factor impairs human thymic recovery from lymphopenia

BACKGROUND: The lymphocyte-depleting antibody alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis (RRMS); however, 50% of patients develop novel autoimmunity after treatment. Most at risk are individuals who reconstitute their T cell pool by proliferating residual...

Descripción completa

Detalles Bibliográficos
Autores principales: Coles, Alasdair J., Azzopardi, Laura, Kousin-Ezewu, Onajite, Mullay, Harpreet Kaur, Thompson, Sara A.J., Jarvis, Lorna, Davies, Jessica, Howlett, Sarah, Rainbow, Daniel, Babar, Judith, Sadler, Timothy J., Brown, J. William L., Needham, Edward, May, Karen, Georgieva, Zoya G., Handel, Adam E., Maio, Stefano, Deadman, Mary, Rota, Ioanna, Holländer, Georg, Dawson, Sarah, Jayne, David, Seggewiss-Bernhardt, Ruth, Douek, Daniel C., Isaacs, John D., Jones, Joanne L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2019
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629095/
https://www.ncbi.nlm.nih.gov/pubmed/31063156
http://dx.doi.org/10.1172/jci.insight.125377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629095/
https://www.ncbi.nlm.nih.gov/pubmed/31063156
http://dx.doi.org/10.1172/jci.insight.125377

Ejemplares similares